Reduced risk of disease progression or death by 63%, with median PFS of 22.2 months in the FRUSICA-2 registration study Innovent Biologics, Inc. ("I...
In TRIUMPH-1, participants on 12 mg retatrutide lost an average of 70.3 lbs (28.3%) over 80 weeks with 45.3% of participants achieving ≥30% weig...
What's Coming to ASCO 2026: Sneak Peek at Transformative Cancer Research The American Society of Clinical Oncology (ASCO) 2026 Annual Meet...
Wegovy® 7.2 mg in a single-dose pen has now been recommended by CHMP for approval in the EU Novo Nordisk expects to launch Wegovy® 7.2 mg in a...
Accelerates how oncology teams assess study feasibility, size opportunity, and generate real-world intelligence Flexible interface and advanced capabili...
Hu-mAtrIx™-Enabled Next-Generation ACVR2A/2B-Targeting Antibody Demonstrates Potential to Become a Bes...
The launch follows Dr. Reddy’s receipt of the Notice of Compliance (NOC) from Health Canada on April 28th, 2026, marking the company’s re...
FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending focused on the develo...
Recently, the novel oral BET inhibitor NHWD-870 HCI, independently developed by Zhejiang Wenda Pharmaceutical Technology Co., Ltd., officially recei...
Amplia and ANZGOG enter into agreement to conduct a clinical study in ovarian cancer evaluating narmafotinib in combination with standard-of-care chemo...
Hantavirus Infection has once again entered public health discussions as global health experts intensify surveillance of zoonotic diseases ...
Fluid overload remains one of the most complex and costly challenges in cardiorenal care, particularly for patients who no longer respond to conventional d...
Analytical Framework Combines AI-Powered Retinal Imaging with Proprietary Circular RNA Biomarkers to Unlock Scalable, Non-Invasive Pathway for Early-Stag...
Expands global intellectual property coverage in markets with greater late-stage breast cancerdiagnoses and higher triple-negative breast cancer incidenc...
© 2026 Biopharma Boardroom. All Rights Reserved.
